More From This Series
More By This Author
 Drug Resistance in Epilepsy: Lessons from Oncology - No. 243
ISBN: 978-0-470-84146-4
Hardcover
254 pages
May 2002
US $170.00
 Add to Cart
This price is valid for United States. Change location to view local pricing and availability. Other Available Formats: E-Book
|
An online version of this product is available through our subscription-based content service. Visit Wiley InterScience now |
Chair's Introduction (V. Ling).
The problem of the drug-resistant epilepsies (J. W. Sander).
Drug resistance molecules: lessons from oncology (George L. Scheffer and Rik J. Scheper).
Drug resistance in epilepsy: the role of the blood-brain barrier (N. Joan Abbott, et al.).
P glycoprotein and the mechanism of multidrug resistance (A. Varadi, et al).
Drug resistance caused by multidrug resistance-associated proteins (J. Wijnholds).
Reversal of multidrug resistance: lessons from clinical oncology (S. E. Bates, et al.).
Clinical development of P glycoprotein modulators in oncology (A. Oza).
Gene expression profiling of epothilone A-resistant cells (P. Atadja, et al.).
Imaging of P glycoprotein function in vivo with PET (N. H. Hendrikse and W. Vaalburg).
Animal models of drug-resistant epilepsy (W. Loscher).
Drug resistance in epilepsy: human epilepsy (S. M. Sisodiya, et al).
Cellular mechanisms of pharmacoresistance in slices from epilepsy surgery (R. A. Deisz).
Functional polymorphisms of the human multidrug resistance (MDR1) gene: correlation with P glycoprotein expression and activity in vivo (U. Brinkmann).
OC144-093, a novel P glycoprotein inhibitor for the enhancement of anti-epileptic therapy (M. J. Newman, et al.).
Closing remarks (V. Ling).
Index of contributors.
Subject Index.
The problem of the drug-resistant epilepsies (J. W. Sander).
Drug resistance molecules: lessons from oncology (George L. Scheffer and Rik J. Scheper).
Drug resistance in epilepsy: the role of the blood-brain barrier (N. Joan Abbott, et al.).
P glycoprotein and the mechanism of multidrug resistance (A. Varadi, et al).
Drug resistance caused by multidrug resistance-associated proteins (J. Wijnholds).
Reversal of multidrug resistance: lessons from clinical oncology (S. E. Bates, et al.).
Clinical development of P glycoprotein modulators in oncology (A. Oza).
Gene expression profiling of epothilone A-resistant cells (P. Atadja, et al.).
Imaging of P glycoprotein function in vivo with PET (N. H. Hendrikse and W. Vaalburg).
Animal models of drug-resistant epilepsy (W. Loscher).
Drug resistance in epilepsy: human epilepsy (S. M. Sisodiya, et al).
Cellular mechanisms of pharmacoresistance in slices from epilepsy surgery (R. A. Deisz).
Functional polymorphisms of the human multidrug resistance (MDR1) gene: correlation with P glycoprotein expression and activity in vivo (U. Brinkmann).
OC144-093, a novel P glycoprotein inhibitor for the enhancement of anti-epileptic therapy (M. J. Newman, et al.).
Closing remarks (V. Ling).
Index of contributors.
Subject Index.
